Clinical trialNCT01723202CompletedPhase 2Interventional

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

SponsorBhavana KondaEnrollment53Follicular Thyroid CancerInsular Thyroid CancerPapillary Thyroid CancerRecurrent Thyroid Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether dabrafenib is more effective when given with or without trametinib in treating thyroid cancer

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bhavana Konda, MD
Ohio State University Comprehensive Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, San Diego
San Diego, California, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts, United States
Ohio State University Medical Center
Columbus, Ohio, United States
the University of Texas-Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dabrafenib →Trametinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Nov 2012
Primary completion: 15 Apr 2022
Completion: 15 Apr 2022
Last update posted: 24 Aug 2025
Registered enrollment: 53
Registry id: NCT01723202

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.